Baijin Life Science Holdings Limited
MNNGFOTCHealthcare● Active
$0.08
+$0.00(+0.00%)
Market Cap$58003000
P/E Ratio—
52W High$0.08
52W Low$0.045
Baijin Life Science Holdings Limited (MNNGF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MNNGF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.14B | $0.05B | $0.09B | $0.06B | $0.04B |
| Cost of Revenue | $0.09B | $0.04B | $0.08B | $0.05B | $0.05B |
| Gross Profit | $0.04B | $0.02B | $0.01B | $0.01B | ($0.01B) |
| Gross Margin %(computed) | 30.97% | 33.72% | 9.01% | 17.55% | -19.90% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.03B | $0.03B | $0.02B | $0.01B | $0.02B |
| Total Operating Expenses | $0.04B | $0.03B | ($0.00B) | $0.02B | $0.03B |
| Operating Income | ($0.00B) | ($0.01B) | $0.01B | ($0.01B) | ($0.05B) |
| Operating Margin %(computed) | -1.47% | -17.84% | 10.98% | -17.70% | -109.96% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.00B) | ($0.01B) | $0.01B | ($0.02B) | ($0.05B) |
| Income Tax Expense | ($0.00B) | $0.00B | $0.00B | $0.00B | ($0.00B) |
| Net Income | ($0.00B) | ($0.01B) | $0.01B | ($0.02B) | ($0.05B) |
| Net Margin %(computed) | -0.23% | -13.88% | 9.99% | -24.68% | -119.53% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.00 | $-0.01 | $0.01 | $-0.04 | $-0.22 |
| Wtd Avg Shares | 0.69B | 0.65B | 0.60B | 0.37B | 0.24B |
| EBITDA | $0.01B | ($0.01B) | $0.01B | ($0.01B) | ($0.05B) |
| EBITDA Margin %(computed) | 4.62% | -11.78% | 12.87% | -15.53% | -104.91% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · HKD · B
Explore more Baijin Life Science Holdings Limited data
About Baijin Life Science Holdings Limited (MNNGF) Income Statement
Baijin Life Science Holdings Limited (MNNGF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, MNNGF reported revenue of $0.14B, gross profit of $0.04B (gross margin 30.97%), and net income of ($0.00B) — a net profit margin of -0.23%.
Frequently asked questions
MNNGF · 4 questionsBaijin Life Science Holdings Limited (MNNGF) reported revenue of $0.14B for 2025, up 152.5% year-over-year.
MNNGF revenueMNNGF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09